Form 4: Integra LifeSciences Holdings Corp: Executive Poul Mojdeh Reports Stock Option and Restricted Stock Unit Grant

Poul Mojdeh, President & CEO of Integra LifeSciences, reports the acquisition of stock options and restricted stock units.

Summary

• Poul Mojdeh, President & CEO of Integra LifeSciences Holdings Corp, filed a Form 4 on January 8, 2025.
• The report details the grant of non-qualified stock options and restricted stock units on January 6, 2025.
• Mojdeh acquired 217,961 non-qualified stock options with an exercise price of $21.7.
• These options vest in four equal installments on the first, second, third, and fourth anniversaries of the grant date.
• Additionally, Mojdeh acquired 103,688 restricted stock units, vesting in three equal annual installments on the first, second, and third anniversaries of the grant date.
• The restricted stock units will be delivered within 30 days following the first business day that occurs immediately following the six month period after the date of her separation of service as deferred compensation.
• The restricted stock units are subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.
• Following the reported transactions, Mojdeh directly owns 217,961 non-qualified stock options and 103,688 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation event. It's neither particularly positive nor negative from an investment perspective.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Industry Context

Executive compensation packages often include stock options and restricted stock units to incentivize performance and align executive interests with shareholder value. This grant is a typical component of executive compensation in publicly traded companies.

Comparison to Industry Standards

• Stock option and RSU grants are common practice for executive compensation in the biotech and medical device industries.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules (25% annually for options, one third annually for RSUs) are fairly standard within the industry.

Stakeholder Impact

• The grant of equity may have a slightly dilutive effect on existing shareholders.
• The vesting schedule incentivizes the executive to remain with the company, which benefits shareholders.

Key Dates